Literature DB >> 32752910

Hematopoietic stem cell transplantation and chimeric antigen receptor T cell for relapsed or refractory diffuse large B-cell lymphoma.

Tao Wang1, Lei Gao1, Yujie Wang1, Wenjun Zhu2, Lili Xu1, Yang Wang1, Wenqin Yue1, Gusheng Tang1, Li Chen1, Jie Chen1, Weiping Zhang1, Xuejun Yu3, Dongge Feng3, Jianmin Yang1.   

Abstract

Aim: Autologous hematopoietic stem cell transplantation (ASCT) is the standard-of-care curative treatment for relapsed or refractory diffuse large B-cell lymphoma (RR-DLBCL), but the relapse rate is usually high. Materials & methods: In this study, we treated 14 RR-DLBCL patients by combining ASCT and anti-CD19 chimeric antigen receptor T-cell therapy.
Results: Eleven (78.57%) patients achieved complete or partial remission. Median duration of progression-free survival was 14.82 months (95% CI: 0.00-31.20 months) with 6-month progression-free survival rate of 64.29% (95% CI: 39.18-89.40%). Median overall survival was not achieved, with 1-year overall survival rate of 65.48% (95% CI: 36.00-94.96%). No neurotoxicity was observed.
Conclusion: Our study demonstrated safety and feasibility of ASCT and anti-CD19 chimeric antigen receptor T-cell treatment for RR-DLBCL patients.

Entities:  

Keywords:  autologous hematopoietic stem cell transplantation; chimeric antigen receptor T-cell therapy; diffuse large B-cell lymphoma; relapsed or refractory; safety

Year:  2020        PMID: 32752910      PMCID: PMC7546158          DOI: 10.2217/imt-2020-0075

Source DB:  PubMed          Journal:  Immunotherapy        ISSN: 1750-743X            Impact factor:   4.196


  42 in total

1.  Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.

Authors:  Michael Crump; Sattva S Neelapu; Umar Farooq; Eric Van Den Neste; John Kuruvilla; Jason Westin; Brian K Link; Annette Hay; James R Cerhan; Liting Zhu; Sami Boussetta; Lei Feng; Matthew J Maurer; Lynn Navale; Jeff Wiezorek; William Y Go; Christian Gisselbrecht
Journal:  Blood       Date:  2017-08-03       Impact factor: 22.113

2.  Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Authors:  Stephen J Schuster; Michael R Bishop; Constantine S Tam; Edmund K Waller; Peter Borchmann; Joseph P McGuirk; Ulrich Jäger; Samantha Jaglowski; Charalambos Andreadis; Jason R Westin; Isabelle Fleury; Veronika Bachanova; S Ronan Foley; P Joy Ho; Stephan Mielke; John M Magenau; Harald Holte; Serafino Pantano; Lida B Pacaud; Rakesh Awasthi; Jufen Chu; Özlem Anak; Gilles Salles; Richard T Maziarz
Journal:  N Engl J Med       Date:  2018-12-01       Impact factor: 91.245

3.  CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.

Authors:  Bertrand Coiffier; Eric Lepage; Josette Briere; Raoul Herbrecht; Hervé Tilly; Reda Bouabdallah; Pierre Morel; Eric Van Den Neste; Gilles Salles; Philippe Gaulard; Felix Reyes; Pierre Lederlin; Christian Gisselbrecht
Journal:  N Engl J Med       Date:  2002-01-24       Impact factor: 91.245

4.  Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma.

Authors:  Carrie A Thompson; Herve Ghesquieres; Matthew J Maurer; James R Cerhan; Pierre Biron; Stephen M Ansell; Catherine Chassagne-Clément; David J Inwards; Thérèse Gargi; Patrick B Johnston; Emmanuelle Nicolas-Virelizier; William R Macon; Marie Peix; Ivana N Micallef; Catherine Sebban; Grzegorz S Nowakowski; Luis F Porrata; George J Weiner; Thomas E Witzig; Thomas M Habermann; Brian K Link
Journal:  J Clin Oncol       Date:  2014-09-29       Impact factor: 44.544

5.  CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.

Authors:  Cameron J Turtle; Laïla-Aïcha Hanafi; Carolina Berger; Theodore A Gooley; Sindhu Cherian; Michael Hudecek; Daniel Sommermeyer; Katherine Melville; Barbara Pender; Tanya M Budiarto; Emily Robinson; Natalia N Steevens; Colette Chaney; Lorinda Soma; Xueyan Chen; Cecilia Yeung; Brent Wood; Daniel Li; Jianhong Cao; Shelly Heimfeld; Michael C Jensen; Stanley R Riddell; David G Maloney
Journal:  J Clin Invest       Date:  2016-04-25       Impact factor: 14.808

6.  CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade.

Authors:  Theodoros Giavridis; Sjoukje J C van der Stegen; Justin Eyquem; Mohamad Hamieh; Alessandra Piersigilli; Michel Sadelain
Journal:  Nat Med       Date:  2018-05-28       Impact factor: 53.440

7.  Chimeric Antigen Receptor-modified Donor Lymphocyte Infusion Improves the Survival of Acute Lymphoblastic Leukemia Patients With Relapsed Diseases After Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Tao Wang; Lei Gao; Xiaoxia Hu; Bin Liu; Jie Chen; Weiping Zhang; Jianmin Wang; Xuejun Yu; Dongge Feng; Alfred E Chang; Wicha Max; Gusheng Tang; Qiao Li; Jianmin Yang
Journal:  J Immunother       Date:  2019-04       Impact factor: 4.456

8.  High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis.

Authors:  T Kewalramani; A D Zelenetz; E E Hedrick; G B Donnelly; S Hunte; A C Priovolos; J Qin; N C Lyons; J Yahalom; S D Nimer; C H Moskowitz
Journal:  Blood       Date:  2000-10-01       Impact factor: 22.113

9.  Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.

Authors:  Marco L Davila; Isabelle Riviere; Xiuyan Wang; Shirley Bartido; Jae Park; Kevin Curran; Stephen S Chung; Jolanta Stefanski; Oriana Borquez-Ojeda; Malgorzata Olszewska; Jinrong Qu; Teresa Wasielewska; Qing He; Mitsu Fink; Himaly Shinglot; Maher Youssif; Mark Satter; Yongzeng Wang; James Hosey; Hilda Quintanilla; Elizabeth Halton; Yvette Bernal; Diana C G Bouhassira; Maria E Arcila; Mithat Gonen; Gail J Roboz; Peter Maslak; Dan Douer; Mark G Frattini; Sergio Giralt; Michel Sadelain; Renier Brentjens
Journal:  Sci Transl Med       Date:  2014-02-19       Impact factor: 17.956

10.  Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia.

Authors:  David T Teachey; Simon F Lacey; Pamela A Shaw; J Joseph Melenhorst; Shannon L Maude; Noelle Frey; Edward Pequignot; Vanessa E Gonzalez; Fang Chen; Jeffrey Finklestein; David M Barrett; Scott L Weiss; Julie C Fitzgerald; Robert A Berg; Richard Aplenc; Colleen Callahan; Susan R Rheingold; Zhaohui Zheng; Stefan Rose-John; Jason C White; Farzana Nazimuddin; Gerald Wertheim; Bruce L Levine; Carl H June; David L Porter; Stephan A Grupp
Journal:  Cancer Discov       Date:  2016-04-13       Impact factor: 39.397

View more
  5 in total

1.  Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma.

Authors:  Jiaying Wu; Yang Cao; Qi Zhang; Wanying Liu; Xiaoxi Zhou; Xi Ming; Fankai Meng; Yicheng Zhang; Chunrui Li; Liang Huang; Jia Wei; Miao Zheng; Shangkun Zhang; Tongcun Zhang; Xiaojian Zhu; Na Wang; Jue Wang; Gaoxiang Wang; Jianfeng Zhou; Bo Liu; Yi Xiao
Journal:  Front Immunol       Date:  2022-05-20       Impact factor: 8.786

Review 2.  Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies.

Authors:  Xinyi Xiao; Yazhuo Wang; Zhengbang Zou; Yufei Yang; Xinyu Wang; Xin Xin; Sanfang Tu; Yuhua Li
Journal:  Front Immunol       Date:  2022-08-23       Impact factor: 8.786

3.  Efficacy and Safety of Innovative Experimental Chimeric Antigen Receptor (CAR) T-cells versus Axicabtagene ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL): Matching Adjusted Indirect Comparisons (MAICs) and Systematic Review.

Authors:  Bayarmagnai Weinstein; Bogdan Muresan; Sara Solano; Antonio Vaz de Macedo; YoonJung Lee; Yu-Chen Su; Yeseul Ahn; Gabriela Henriquez; Cristina Camargo; Gwang-Jin Kim; David O Carpenter
Journal:  Innov Pharm       Date:  2021-09-22

4.  The risk factors and early predictive model of hematotoxicity after CD19 chimeric antigen receptor T cell therapy.

Authors:  Yang Wang; Zhiqiang Song; Yuke Geng; Lei Gao; Lili Xu; Gusheng Tang; Xiong Ni; Li Chen; Jie Chen; Tao Wang; Weijia Fu; Dongge Feng; Xuejun Yu; Libing Wang; Jianmin Yang
Journal:  Front Oncol       Date:  2022-09-30       Impact factor: 5.738

5.  Sequential CD19/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma.

Authors:  Jiaying Wu; Fankai Meng; Yang Cao; Yicheng Zhang; Xiaojian Zhu; Na Wang; Jue Wang; Lifang Huang; Jianfeng Zhou; Yi Xiao
Journal:  Blood Cancer J       Date:  2021-07-15       Impact factor: 11.037

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.